Alpha-MSH (α-Melanocyte-Stimulating Hormone)
Alpha-MSH is an endogenous tridecapeptide derived from POMC processing that acts as a non-selective melanocortin receptor agonist, regulating pigmentation, inflammation, appetite, and sexual function through MC1R, MC3R, MC4R, and MC5R signaling.
Alpha-melanocyte-stimulating hormone (alpha-MSH) is an endogenous tridecapeptide produced by post-translational processing of proopiomelanocortin (POMC) in the pituitary gland, hypothalamus, and peripheral tissues. It acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, mediating a remarkably diverse array of physiological functions including skin pigmentation, anti-inflammatory signaling, appetite regulation, and sexual behavior.
Overview
Alpha-MSH is one of several bioactive peptides produced from the 241-amino acid POMC precursor protein. POMC processing by prohormone convertases PC1 and PC2 yields alpha-MSH (POMC 138-150), beta-MSH, gamma-MSH, ACTH, and beta-endorphin in a tissue-specific manner. In the anterior pituitary, POMC is primarily cleaved to ACTH; in the intermediate pituitary and hypothalamic arcuate nucleus, further processing yields alpha-MSH and beta-endorphin (Cawley et al., 2016).
Alpha-MSH was first identified in the 1950s as the factor responsible for melanophore dispersion in amphibian skin. Its role has since expanded enormously: it is now recognized as a key mediator of energy homeostasis through hypothalamic MC4R signaling, a potent endogenous anti-inflammatory peptide acting through MC1R on immune cells, and a modulator of sexual behavior via MC3R/MC4R in limbic circuits. The extremely short plasma half-life of native alpha-MSH (~3-5 minutes due to rapid aminopeptidase degradation) drove the development of more stable synthetic analogs including afamelanotide and Melanotan II.
Mechanism of Action
Alpha-MSH exerts its biological effects through four of the five melanocortin receptor subtypes:
- MC1R (Pigmentation and Anti-inflammation): On melanocytes, alpha-MSH binding activates Gs/cAMP/PKA signaling, driving MITF-mediated transcription of melanogenic enzymes (tyrosinase, TYRP1, DCT) and shifting melanin synthesis toward photoprotective eumelanin. On macrophages, monocytes, and dendritic cells, MC1R activation suppresses NF-kappaB nuclear translocation, reducing production of TNF-alpha, IL-1beta, IL-6, and IL-8 (Catania et al., 2004)
- MC3R (Energy Partitioning): Expressed in the arcuate nucleus and peripheral tissues, MC3R mediates nutrient partitioning between fat and lean mass. MC3R also functions as a presynaptic autoreceptor on POMC neurons, modulating alpha-MSH release in a negative feedback loop (Renquist et al., 2011)
- MC4R (Appetite and Sexual Function): In hypothalamic PVN neurons, alpha-MSH activation of MC4R produces anorexigenic signaling through cAMP/PKA and Gq/PLC pathways, reducing food intake and increasing energy expenditure. In limbic circuits, MC4R activation stimulates oxytocinergic and dopaminergic pathways involved in sexual arousal (Cone, 2005)
- MC5R (Exocrine Function): Expressed in sebaceous and lacrimal glands, MC5R mediates sebum secretion and exocrine gland regulation. MC5R-knockout mice exhibit severe defects in water repulsion of fur due to altered lipid secretion
Reconstitution Calculator
Alpha-MSH (α-Melanocyte-Stimulating Hormone)
Alpha-melanocyte-stimulating hormone (alpha-MSH) is an endogenous tridecapeptide
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
PT-141/Bremelanotide Clinical Trials (RECONNECT Studies)
Kingsberg et al. (2019) reported results from the two pivotal RECONNECT Phase III trials (Studies 301 and 302) enrolling 1,247 premenopausal women with generalized acquired HSDD. Patients self-administered bremelanotide 1.75 mg SC as needed before anticipated sexual activity for 24 weeks. Bremelanotide significantly increased the number of satisfying sexual events (SSE) per month (mean increase 1.0 vs placebo, p<0.001) and reduced Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) scores. Approximately 25% of bremelanotide patients achieved clinically meaningful improvement versus 17% for placebo. These results supported FDA approval of Vyleesi in June 2019.
Melanocortin-Oxytocin Pathway
The MC4R-oxytocin axis is the primary efferent pathway mediating melanocortin pro-sexual effects. Argiolas & Melis (2013) demonstrated that oxytocin antagonists administered intracerebroventricularly or into the ventral subiculum of the hippocampus completely blocked alpha-MSH and bremelanotide-induced erections in rats, confirming oxytocin as an essential downstream mediator. PVN oxytocinergic neurons project to the spinal cord (lumbosacral autonomic centers) and to limbic areas (VTA, amygdala), providing both autonomic (pro-erectile) and motivational (pro-desire) output.
Comparison with PDE5 Inhibitors
The fundamental distinction is mechanism site: melanocortin agonists are central (brain), PDE5 inhibitors are peripheral (penis). This has several clinical implications:
- Desire vs arousal: Melanocortins enhance desire and motivation; PDE5 inhibitors enhance the erectile response to existing desire
- Female efficacy: PDE5 inhibitors have consistently failed in female sexual dysfunction trials because female arousal disorder is primarily central. Bremelanotide succeeded because it targets central mechanisms
- PDE5i non-responders: Approximately 30–40% of ED patients fail PDE5 inhibitors. Diamond et al. (2004) showed bremelanotide efficacy in this population, including diabetic and post-prostatectomy patients
- Combination potential: Because the mechanisms are non-overlapping, there is theoretical rationale for combining melanocortin agonists (central desire) with PDE5 inhibitors (peripheral erection), though this has not been studied in formal trials
Neuroprotection
Catania et al. (2010)) reviewed neuroprotective effects of alpha-MSH in models of cerebral ischemia, traumatic brain injury, and neuroinflammation. Alpha-MSH reduces brain inflammation through MC1R and MC4R on microglia and astrocytes, suppressing reactive gliosis and reducing infarct volume in stroke models. The peptide also attenuates blood-brain barrier disruption and reduces edema formation following CNS injury.
Immunomodulation
Luger et al. (2003) demonstrated that alpha-MSH modulates adaptive immunity by influencing dendritic cell maturation and T-cell polarization. MC1R signaling in dendritic cells promotes regulatory T-cell (Treg) differentiation and suppresses Th1/Th17 responses, suggesting a role in maintaining immune tolerance. This has implications for autoimmune diseases and transplant rejection.
Sexual Function
Alpha-MSH, through MC3R and MC4R in hypothalamic and limbic structures, modulates sexual arousal and erectile function. Argiolas & Melis (2013) established that alpha-MSH activates oxytocinergic neurons in the PVN, triggering oxytocin release that descends to sacral parasympathetic centers mediating genital arousal. This endogenous pathway is the basis for the pro-sexual effects of synthetic melanocortin agonists including PT-141/bremelanotide.
Appetite and Energy Homeostasis
The melanocortin theory of energy regulation, formalized by Cone (2005), established that alpha-MSH released from POMC neurons in the arcuate nucleus acts as the primary endogenous anorexigenic signal at MC4R in the paraventricular nucleus. This signaling is opposed by agouti-related peptide (AgRP), an endogenous MC4R inverse agonist released from adjacent NPY/AgRP neurons. The balance between alpha-MSH and AgRP tone at MC4R is the central integrator of peripheral energy signals (leptin, insulin, ghrelin) with central appetite regulation.
Loss-of-function mutations in MC4R are the most common monogenic cause of human obesity, affecting approximately 5% of severely obese individuals. POMC deficiency, which eliminates alpha-MSH production, causes severe early-onset obesity, adrenal insufficiency, and red hair pigmentation (Krude et al., 1998).
Pigmentation
Alpha-MSH is the primary physiological regulator of constitutive and facultative skin pigmentation. Upon UV exposure, keratinocytes upregulate POMC expression and secrete alpha-MSH in a paracrine fashion, stimulating neighboring melanocytes through MC1R. This UV-induced melanogenesis constitutes the tanning response. Slominski et al. (2005) demonstrated that the cutaneous melanocortin system operates as a local neuroendocrine circuit, with keratinocytes, melanocytes, and Langerhans cells all expressing components of the POMC/MC1R axis.
Genetic variants of MC1R that reduce alpha-MSH signaling (R151C, R160W, D294H) are associated with the red hair/fair skin phenotype, increased pheomelanin:eumelanin ratio, and elevated melanoma risk independent of UV exposure.
MC4R Knockout Models
MC4R knockout mice exhibit significant impairment in sexual behavior, including reduced mounting frequency, increased latency to intromission, and decreased ejaculation frequency in males, and reduced lordosis quotient in females. These phenotypes are independent of the obesity caused by MC4R loss, as pair-fed MC4R knockouts still show sexual deficits. Van der Ploeg et al. (2002) demonstrated that MC4R is both necessary and sufficient for melanocortin-induced sexual responses, as selective MC4R agonists reproduce the pro-sexual effects while MC3R-selective compounds do not produce erection in animal models.
Male vs Female Sexual Dysfunction
Bremelanotide has been studied in both male and female sexual dysfunction, with different clinical outcomes:
- Female HSDD: FDA-approved indication. The RECONNECT trials demonstrated efficacy for desire and distress endpoints in premenopausal women (Kingsberg et al., 2019)
- Male ED: Diamond et al. (2006) demonstrated intranasal bremelanotide efficacy in men with ED, including those who had failed sildenafil. RigiScan monitoring showed erections in 67% of subjects. However, the clinical program for male ED was not pursued to approval due to transient blood pressure elevations with the intranasal formulation and strategic focus on female HSDD
- Female arousal: Diamond et al. (2006) used vaginal photoplethysmography to confirm bremelanotide increased genital arousal (vaginal pulse amplitude) in women with FSAD during erotic stimulation
Anti-Inflammatory Signaling
Catania et al. (2004) conducted a comprehensive review establishing alpha-MSH as one of the most potent endogenous anti-inflammatory peptides. The anti-inflammatory mechanism operates through MC1R-dependent inhibition of NF-kappaB: alpha-MSH binding increases intracellular cAMP, which activates PKA-mediated phosphorylation of IkappaB, preventing NF-kappaB nuclear translocation and suppressing transcription of pro-inflammatory cytokines. This pathway has been demonstrated in macrophages, monocytes, neutrophils, dendritic cells, endothelial cells, and brain microglia.
Additional anti-inflammatory mechanisms include inhibition of neopterin and nitric oxide production, reduced expression of adhesion molecules (ICAM-1, VCAM-1) on endothelial cells, and suppression of chemokine production. These effects operate at picomolar to nanomolar concentrations, indicating high physiological potency.
Safety Profile
As an endogenous peptide, alpha-MSH has a well-characterized physiological safety profile:
- Endogenous concentrations: Circulating alpha-MSH levels are typically in the picomolar range (10-50 pg/mL) and rise during inflammation, UV exposure, and stress
- Rapid degradation: The extremely short half-life (~3-5 minutes) limits systemic exposure and prevents sustained receptor overstimulation. This rapid clearance is both a safety feature and a limitation for therapeutic use
- Exogenous administration: Research protocols using IV or SC alpha-MSH have reported transient facial flushing, mild nausea at high doses, and transient tachycardia. These effects are less pronounced than with more potent synthetic analogs due to rapid degradation
- Theoretical concerns: Chronic supraphysiological MC1R stimulation could promote melanocyte proliferation; chronic MC4R activation causes nausea and blood pressure changes. These concerns apply primarily to synthetic analogs rather than the native peptide
- POMC deficiency syndrome: Complete absence of alpha-MSH (via POMC mutations) causes severe early-onset obesity, adrenal insufficiency, and red hair, demonstrating the peptide's essential physiological role
Pharmacokinetic Profile
Alpha-MSH (α-Melanocyte-Stimulating Hormone) — Pharmacokinetic Curve
Endogenous; research: IV, SC, ICV injectionQuick Start
- Route
- Endogenous; research: IV, SC, ICV injection
Molecular Structure
- Weight
- 1664.8 Da
- CAS
- 581-05-5
Research Indications
Immune
Potent anti-inflammatory effects via NF-κB inhibition, adhesion molecule suppression, and pro-inflammatory cytokine reduction. Validated in animal models of dermatitis, vasculitis, arthritis, IBD, and asthma (PMID: 17934097, 10816650).
Direct antimicrobial effects against fungal and bacterial pathogens without the toxicity associated with other antimicrobial peptides. Preclinical evidence (PMC4130143).
Dermatological
Primary physiological regulator of melanin synthesis via MC1R on melanocytes. Secreted by keratinocytes after UV exposure. Well-established endocrine mechanism (PMC10463388).
C-terminal tripeptide KPV retains anti-inflammatory activity without pigmentary effects. Effective in irritant and allergic contact dermatitis, cutaneous vasculitis, and fibrosis models (PMID: 18612139).
Neurological
Modulates CNS inflammation through activation of descending anti-inflammatory neural pathways and effects on glial cells. Preclinical models of brain inflammation (PMID: 11268347).
Reduces fever through central melanocortin receptor activation. Validated in experimentally induced fever animal models.
Research Protocols
intranasal Injection
However, the clinical program for male ED was not pursued to approval due to transient blood pressure elevations with the intranasal formulation and strategic focus on female HSDD - Female arousal: [Diamond et al. This concern led to abandonment of the intranasal formulation in favor of subcutaneous
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 1.75 mg | Per protocol | 24 weeks |
intracerebroventricular Injection
Administered via intracerebroventricular.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 1.75 mg | Per protocol | 24 weeks |
subcutaneous Injection
This concern led to abandonment of the intranasal formulation in favor of subcutaneous delivery - Hyperpigmentation: Focal darkening of facial skin and gingival tissue with repeated use, reflecting MC1R agonist activity stimulating melanocyte melanogenesis.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Contraindications | 1.75 mg | Per protocol | 24 weeks |
Interactions
Peptide Interactions
Alpha-MSH is derived from the same POMC precursor as ACTH via proteolytic cleavage (ACTH1-13 forms desacetyl alpha-MSH). Both activate melanocortin receptors: alpha-MSH is a non-selective agonist at MC1R (Ki=0.23 nM), MC3R, MC4R, MC5R, while ACTH additionally activates MC2R exclusively. Both exert glucocorticoid-independent anti-inflammatory and immunomodulatory effects through melanocortin receptor signaling on immune cells (Catania et al., 2004). Combined melanocortin signaling provides broader receptor coverage.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-MSH that retains its anti-inflammatory activity without broader hormonal effects. Both suppress NF-kB nuclear translocation and downregulate TNF-alpha, IL-1beta, and IL-6 while upregulating the anti-inflammatory cytokine IL-10. KPV binds MC1R and MC3R with similar anti-inflammatory potency to full-length alpha-MSH (Brzoska et al., 2008).
Both alpha-MSH and neurotensin are neuropeptides with anti-inflammatory properties acting through distinct receptor systems (melanocortin receptors vs. NTS1/NTS2). Alpha-MSH suppresses neuroinflammation via NF-kB inhibition while neurotensin modulates dopaminergic and immune signaling. No known antagonistic interactions; they operate through independent signaling cascades.
Alpha-MSH and cathelicidin LL-37 are both antimicrobial peptides co-expressed in inflamed skin tissue. Alpha-MSH has direct antimicrobial activity against bacterial and fungal pathogens via its C-terminal residues, while LL-37 kills microbes through membrane disruption. Both are upregulated in inflammatory skin conditions. Alpha-MSH provides immunomodulatory suppression of NF-kB while LL-37 activates innate immune recruitment. Complementary mechanisms without antagonism (Singh & Singh, 2014).
The fundamental distinction is mechanism site: melanocortin agonists are central (brain), PDE5 inhibitors are peripheral (penis). This has several clinical implications: 1. Desire vs arousal: Melanocortins enhance desire and motivation; PDE5 inhibitors enhance the erectile response to existing de...
What to Expect
What to Expect
Rapid onset expected; half-life of ~3-5 minutes (plasma) indicates fast-acting pharmacokinetics
Due to short half-life (~3-5 minutes (plasma)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Extensive peer-reviewed research base
Caution
- Short half-life may require frequent dosing
Frequently Asked Questions
References (11)
- [1]Catania A, Gatti S, Colombo G, Lipton JM Targeting melanocortin receptors as a novel strategy to control inflammation Pharmacol Rev (2004)
- [9]Dores RM, Liang L, Davis P, et al — Melanocortin receptor evolution provides insights into ligand-receptor coevolution Mol Cell Endocrinol (2022)
- [10]Montero-Melendez T et al — The melanocortin agonist AP214 exerts anti-inflammatory effects in mice and human subjects Br J Pharmacol (2022)
- [11]Israeli H et al — Cryo-EM structure of active MC4R reveals mechanism of satiation signaling Science (2021)
- [7]Luger TA, Scholzen TE, Brzoska T, et al Cutaneous immunomodulation and coordination of skin stress responses by alpha-melanocyte-stimulating hormone Ann N Y Acad Sci (2003)
- [8]Renquist BJ, Murphy JG, Larsen ES, et al Melanocortin-3 receptor regulates the normal fasting response Proc Natl Acad Sci USA (2011)
- [2]Slominski A, Tobin DJ, Shibahara S, Wortsman J Melanin pigmentation in mammalian skin and its hormonal regulation Physiol Rev (2005)
- [3]
- [4]Catania A Neuroprotective actions of melanocortins: a therapeutic opportunity Trends Neurosci (2010)
- [5]Montero-Melendez T, Gobbetti T, Cooray SN, et al Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects J Immunol (2015)
- [6]Krude H, Biebermann H, Luck W, et al Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans Nat Genet (1998)
AHK (Tripeptide-3)
AHK (Tripeptide-3) is a three-amino-acid peptide (Ala-His-Lys) investigated for its effects on hair growth, wound healing, and skin rejuvenation. It activates fibroblasts and modulates VEGF signaling to promote collagen synthesis and angiogenesis.
Anti-Müllerian Hormone (AMH)
Anti-Müllerian Hormone (AMH) is a TGF-β superfamily glycoprotein produced by granulosa cells and Sertoli cells that serves as a gold-standard biomarker for ovarian reserve assessment, PCOS diagnosis, and male reproductive function. Recombinant AMH is under preclinical investigation as a non-hormonal contraceptive.